Adimmune (TPE:4142) ROC (Joel Greenblatt) %: 16.85% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4142 Adimmune Corp TPE:4142
50 GF Score
Price NT$16.80
GF Value NT$25.76
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Adimmune ROC (Joel Greenblatt) %?

Adimmune TPE:4142 -3.17% 50 ROC (Joel Greenblatt) % is 16.85% as of Dec. 2025. GuruFocus rates TPE:4142 with a GF Score™ of 50/100 and a GF Value™ of NT$25.76 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,323 Biotechnology companies, Adimmune ranks better than 76.87% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Adimmune's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 16.85%.

The historical rank and industry rank for Adimmune's ROC (Joel Greenblatt) % or its related term are showing as below:

TPE:4142' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21.76   Med: -7.37   Max: 42.14
Current: -6.14

During the past 13 years, Adimmune's highest ROC (Joel Greenblatt) % was 42.14%. The lowest was -21.76%. And the median was -7.37%.

TPE:4142's ROC (Joel Greenblatt) % is ranked better than
76.87% of 1323 companies
in the Biotechnology industry
Industry Median: -297.52 vs TPE:4142: -6.14

Adimmune's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Adimmune  (TPE:4142) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Adimmune ROC (Joel Greenblatt) % Related Terms


Adimmune ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Adimmune's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune ROC (Joel Greenblatt) % Chart

Adimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 4.01 -14.61 -6.06 -6.37

Adimmune Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.12 -21.29 -19.06 -2.33 16.85

TPE:4142 vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Adimmune's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adimmune ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adimmune's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Adimmune's ROC (Joel Greenblatt) % falls into.


TPE:4142
50GF Score
Adimmune Corp TPE:4142
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adimmune ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(438.484 + 786.054 + 346.011) - (232.882 + 0 + 18.817)
=1318.85

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(144.864 + 571.084 + 314.203) - (258.011 + 0 + 51.093)
=721.047

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Adimmune for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=844.684/( ( (3974.069 + max(1318.85, 0)) + (4014.536 + max(721.047, 0)) )/ 2 )
=844.684/( ( 5292.919 + 4735.583 )/ 2 )
=844.684/5014.251
=16.85 %

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 16.85% mean?
Adimmune (TPE:4142) has a ROC (Joel Greenblatt) % of 16.85% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Adimmune and its competitors. According to the industry distribution chart, Adimmune ranks #306 out of 1323 companies in the Biotechnology industry, placing it in the top 23.1%.
Is Adimmune's ROC (Joel Greenblatt) % too high?
Adimmune's current ROC (Joel Greenblatt) % is 16.85%. Based on the distribution chart, Adimmune ranks #306 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adimmune has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adimmune ranks #306 out of 1323 companies for ROC (Joel Greenblatt) %. This places Adimmune in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Adimmune and its competitors. Adimmune's current ROC (Joel Greenblatt) % is 16.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.76, compared to a current price of NT$16.80 — trading 34.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 16.85%. Adimmune's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Adimmune (TPE:4142), the current ROC (Joel Greenblatt) % is 16.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$16.80 is trading 34.8% below its estimated GF Value™ of NT$25.76. GuruFocus considers Adimmune to be Possible Value Trap.

Key valuation signals for TPE:4142:

  • ROC (Joel Greenblatt) %: 16.85%
  • GF Value™: NT$25.76 vs. price of NT$16.80 (34.8% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
50GF Score

Get the complete analysis for TPE:4142

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.80
Price
NT$25.76
GF Value